Evaluation for the Efficacy of Exon-Skipping Therapy Using In Vivo Assessment of Skeletal Muscle Function and Fragility.

Yuki Ashida, Katsura Minegishi, Norio Motohashi, Yoshitsugu Aoki, Takashi Yamada

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuki AshidaDepartment of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

Katsura MinegishiDepartment of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

Norio MotohashiCenter of Neurology and Psychiatry, National Institute of Neuroscience, Tokyo, Japan.

Yoshitsugu AokiDepartment of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

Takashi YamadaGraduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. yama1976@hiroshima-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Splice-switching oligonucleotide (SSO) therapy is expected to be a promising treatment for muscular diseases such as Duchenne muscular dystrophy (DMD). Preclinical studies using animal models of muscle diseases are essential for the development of SSO therapy. In addition to the histological and biochemical analyses, an in vivo muscle torque measurement using supramaximal electrical stimulation has become a standard protocol for the evaluation of drug efficacy. Nevertheless, in order to accurately measure the torque production in animal models, there are some critical points that should be brought to attention. In this chapter, we describe detailed methods for in vivo muscle torque measurement in animal models for DMD, i.e., mdx52 mouse and canine X-linked muscular dystrophy in Japan (CXMD

Indexed as

ExonsGenetic TherapyMuscle, SkeletalMuscular Dystrophy, DuchenneAnimalsDisease Models, AnimalDogsMiceMice, Inbred mdxTorqueEccentric contractionIsometric contractionMuscle functionProlonged force depression

Identifiers

PMID41028678

DOI10.1007/s00421-015-3124-x

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.